Abstract | AIMS: Intensive glycaemic control in type 2 diabetes achieved by insulin is generally accompanied by body weight gain. This study was performed to emphasize the meaning of caloric analysis of urine and faeces for energy balance. METHODS: RESULTS: CONCLUSIONS: Our data clearly show renal contribution to the body's energy control by urinary glucose excretion (UGE) during antidiabetic treatment. The undesired retained energy could be reduced via additional UGE or via simultaneous reduction of energy uptake and/or energy retention.
|
Authors | R Elvert, A Wille, J Wandschneider, U Werner, H Glombik, A W Herling |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 15
Issue 4
Pg. 324-34
(Apr 2013)
ISSN: 1463-1326 [Electronic] England |
PMID | 23121319
(Publication Type: Journal Article)
|
Copyright | © 2012 Blackwell Publishing Ltd. |
Chemical References |
- AVE2268
- Blood Glucose
- Glp1r protein, rat
- Glucagon-Like Peptide-1 Receptor
- Glucosides
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin, Long-Acting
- Peptides
- Receptors, Glucagon
- Slc5a2 protein, rat
- Sodium-Glucose Transporter 2
- Sodium-Glucose Transporter 2 Inhibitors
- Insulin Glargine
- lixisenatide
|
Topics |
- Animals
- Blood Glucose
(drug effects)
- Diabetes Mellitus, Experimental
(drug therapy, metabolism)
- Diabetes Mellitus, Type 2
(drug therapy, metabolism)
- Glucagon-Like Peptide-1 Receptor
- Glucosides
(pharmacology)
- Glycated Hemoglobin
(drug effects)
- Hypoglycemic Agents
(pharmacology)
- Insulin Glargine
- Insulin, Long-Acting
(pharmacology)
- Kidney
(drug effects)
- Male
- Peptides
(pharmacology)
- Rats
- Rats, Zucker
- Receptors, Glucagon
(agonists)
- Sodium-Glucose Transporter 2
- Sodium-Glucose Transporter 2 Inhibitors
- Weight Gain
(drug effects)
|